A leading pharmaceutical company wanted to supply its portfolio of treatments for a rare congenital disease into new markets on an unlicensed basis. This required the company to navigate the varied regulatory landscapes across different markets and understand the range of possible distribution channels for making product available, including unlicensed commercial sales, compassionate use, and Named Patient Programs. The company wanted to find a partner with the right knowledge and expertise to help them face this challenge.
The company partnered with WEP Clinical to set up supply chains to get the product into the relevant markets. WEP Clinical utilized its expertise in supplying unlicensed products to navigate the complicated regulatory landscape in each country and conduct patient and physician validation to ensure that product could be supplied. Through these distribution channels WEP Clinical has successfully supplied the products to the UK, Europe, the Middle East, and South America, with the option to expand to additional geographies globally.